Prospective study of ONCOS-102 and dendritic cell vaccine therapy in prostate cancer

Trial Profile

Prospective study of ONCOS-102 and dendritic cell vaccine therapy in prostate cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Dendritic cell vaccines (Primary) ; ONCOS 102 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors SOTIO
  • Most Recent Events

    • 02 Nov 2017 According to a Targovax media release, the company is planning to recruit the first patient in this trial in H2 2017 and interim data expected in 2H 2018.
    • 03 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top